Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eosinophil-guided Prednisone in COPD Exacerbation (EoPred-ICU)
NCT03981081Phase 4Unknown
- Sponsor
- Fattouma Bourguiba University Hospital
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of prednisone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Fattouma Bourguiba University Hospital. Primary endpoint: proportion of unventilated patients at day 6. Status: unknown.
02
Drugs
prednisone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03981081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981081.